Denmark's Novo Nordisk has entered into a deal to co-develop and commercialize oral formulations of its Insulin analogues using Irish firm Merrion Pharmaceuticals' GIPET technology. Under the agreement, Merrion will receive up to $58.0 million based on achievement of certain milestones, as well as royalties on sales. Novo will pay for the development and commercialization of the product candidates and Merrion will fund the first clinical batches.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze